16 November 2020: Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases
We run statistic cookies to help us understand how visitors interact with our website by collecting and reporting information anonymously. By continuing to use our website you consent to cookies being used.YesPrivacy policy